BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sánchez PJ, Steichen J, Givner LB, Jennings TL, Top FH, Carlin D. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17:110-115. [PMID: 9493805 DOI: 10.1097/00006454-199802000-00006] [Cited by in Crossref: 140] [Cited by in F6Publishing: 130] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Robinson JL, Le Saux N. The author responds. Paediatrics & Child Health 2015;20:464-5. [DOI: 10.1093/pch/20.8.463a] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
2 Reff ME, Hariharan K, Braslawsky G. Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control 2002;9:152-66. [PMID: 11965235 DOI: 10.1177/107327480200900207] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
3 Kusuda S, Koizumi T, Sakai T, Fujimura M, Nishida H, Togari H. Results of clinical surveillance during the Japanese first palivizumab season in 2002-2003. Pediatr Int 2006;48:362-8. [PMID: 16911080 DOI: 10.1111/j.1442-200X.2006.02222.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
4 Georgescu G, Chemaly RF. Palivizumab: where to from here? Expert Opin Biol Ther 2009;9:139-47. [PMID: 19063700 DOI: 10.1517/14712590802610692] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
5 Weisman LE. Current respiratory syncytial virus prevention strategies in high-risk infants. Pediatr Int 2002;44:475-80. [PMID: 12225544 DOI: 10.1046/j.1442-200x.2002.01613.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
6 Pons JM, Tebé C, Paladio N, Garcia-Altes A, Danés I, Valls-I-Soler A. Meta-analysis of passive immunoprophylaxis in paediatric patients at risk of severe RSV infection. Acta Paediatr 2011;100:324-9. [PMID: 20950412 DOI: 10.1111/j.1651-2227.2010.02059.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
7 Forbes ML, Kumar VR, Yogev R, Wu X, Robbie GJ, Ambrose CS. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Hum Vaccin Immunother 2014;10:2789-94. [PMID: 25483663 DOI: 10.4161/hv.29635] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
8 Rainwater-Lovett K, Uprety P, Persaud D. Advances and hope for perinatal HIV remission and cure in children and adolescents. Curr Opin Pediatr 2016;28:86-92. [PMID: 26709685 DOI: 10.1097/MOP.0000000000000304] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
9 Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M, Schneider JH, Fretz J, Kokai-Kun JF, Mond JJ, Kramer WG, Fischer GW. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother 2009;53:2879-86. [PMID: 19380597 DOI: 10.1128/AAC.01565-08] [Cited by in Crossref: 54] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
10 Baraldi E, Lanari M, Manzoni P, Rossi GA, Vandini S, Rimini A, Romagnoli C, Colonna P, Biondi A, Biban P, Chiamenti G, Bernardini R, Picca M, Cappa M, Magazzù G, Catassi C, Urbino AF, Memo L, Donzelli G, Minetti C, Paravati F, Di Mauro G, Festini F, Esposito S, Corsello G. Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants. Ital J Pediatr 2014;40:65. [PMID: 25344148 DOI: 10.1186/1824-7288-40-65] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 9.0] [Reference Citation Analysis]
11 Xiao J, Horst S, Hinkle G, Cao X, Kocak E, Fang J, Young D, Khazaeli M, Agnese D, Sun D, Martin E Jr. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients. Cancer Biother Radiopharm 2005;20:16-26. [PMID: 15778575 DOI: 10.1089/cbr.2005.20.16] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
12 Sánchez PJ. Immunoprophylaxis of respiratory syncytial virus disease: . The Pediatric Infectious Disease Journal 2000;19:791-801. [DOI: 10.1097/00006454-200008000-00033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
13 Kalergis AM, Soto JA, Gálvez NMS, Andrade CA, Fernandez A, Bohmwald K, Bueno SM. Pharmacological management of human respiratory syncytial virus infection. Expert Opin Pharmacother 2020;21:2293-303. [PMID: 32808830 DOI: 10.1080/14656566.2020.1806821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Oral HB, Ozakin C, Akdiş CA. Back to the future: antibody-based strategies for the treatment of infectious diseases. Mol Biotechnol 2002;21:225-39. [PMID: 12102547 DOI: 10.1385/MB:21:3:225] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 Sandritter T. Palivizumab for respiratory syncytial virus prophylaxis. Journal of Pediatric Health Care 1999;13:191-5. [DOI: 10.1016/s0891-5245(99)90039-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
16 Wright M, Piedimonte G. Respiratory syncytial virus prevention and therapy: Past, present, and future: RSV Prevention and Therapy. Pediatr Pulmonol 2011;46:324-47. [DOI: 10.1002/ppul.21377] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 6.9] [Reference Citation Analysis]
17 Chirico G, Ravasio R, Sbarigia U. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Ital J Pediatr 2009;35:4. [PMID: 19490659 DOI: 10.1186/1824-7288-35-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
18 [DOI: 10.1101/2020.12.03.409318] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Carbonell-estrany X, Quero J, Bustos G, Cotero A, Doménech E, Figueras-aloy J, Fraga JM, García LG, García-alix A, Del Río MG, Krauel X, Sastre JBL, Narbona E, Roqués V, Hernández SS, Zapatero M. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study: . The Pediatric Infectious Disease Journal 2000;19:592-7. [DOI: 10.1097/00006454-200007000-00002] [Cited by in Crossref: 100] [Cited by in F6Publishing: 94] [Article Influence: 4.5] [Reference Citation Analysis]
20 Jar AM, Osorio FA, López OJ. Mouse × pig chimeric antibodies expressed in Baculovirus retain the same properties of their parent antibodies. Biotechnol Progress 2009;25:516-23. [DOI: 10.1002/btpr.113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
21 López EL, Contrini MM, Glatstein E, González Ayala S, Santoro R, Allende D, Ezcurra G, Teplitz E, Koyama T, Matsumoto Y, Sato H, Sakai K, Hoshide S, Komoriya K, Morita T, Harning R, Brookman S. Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother 2010;54:239-43. [PMID: 19822704 DOI: 10.1128/AAC.00343-09] [Cited by in Crossref: 71] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
22 Park KH, Shin JH, Lee EH, Seo WH, Kim YK, Song DJ, Choi BM, Choung JT, Hong YS. Seasonal Variations of Respiratory Syncytial Virus Infection among the Children under 60 Months of Age with Lower Respiratory Tract Infections in the Capital Area, the Republic of Korea, 2008-2011. J Korean Soc Neonatol 2012;19:195. [DOI: 10.5385/jksn.2012.19.4.195] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
23 Andabaka T, Nickerson JW, Rojas-reyes MX, Rueda JD, Vrca VB, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children: Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Evid -Based Child Health 2013;8:2243-376. [DOI: 10.1002/ebch.1950] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
24 Brandenburg A, Neijens H, Osterhaus A. Pathogenesis of RSV lower respiratory tract infection: implications for vaccine development. Vaccine 2001;19:2769-82. [DOI: 10.1016/s0264-410x(00)00536-3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
25 Hui C, Paes B, Papenburg J, Mitchell I, Li A, Lanctôt KL; CARESS Investigators. Palivizumab Adherence and Outcomes in Canadian Aboriginal Children. Pediatr Infect Dis J 2016;35:1187-93. [PMID: 27331856 DOI: 10.1097/INF.0000000000001282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
26 Hussman JM, Li A, Paes B, Lanctôt KL. A review of cost–effectiveness of palivizumab for respiratory syncytial virus. Expert Review of Pharmacoeconomics & Outcomes Research 2014;12:553-67. [DOI: 10.1586/erp.12.45] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
27 Lacaze-Masmonteil T, Seidenberg J, Mitchell I, Cossey V, Cihar M, Csader M, Baarsma R, Valido M, Pollack PF, Groothuis JR; Second Season Safety Study Group. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. Drug Saf 2003;26:283-91. [PMID: 12608889 DOI: 10.2165/00002018-200326040-00005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
28 Valls-Comamala V, Guivernau B, Bonet J, Puig M, Perálvarez-Marín A, Palomer E, Fernàndez-Busquets X, Altafaj X, Tajes M, Puig-Pijoan A, Vicente R, Oliva B, Muñoz FJ. The antigen-binding fragment of human gamma immunoglobulin prevents amyloid β-peptide folding into β-sheet to form oligomers. Oncotarget 2017;8:41154-65. [PMID: 28467807 DOI: 10.18632/oncotarget.17074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
29 Greenough A, Thomas M. Respiratory syncytial virus prevention: past and present strategies. Expert Opin Pharmacother 2000;1:1195-201. [PMID: 11249487 DOI: 10.1517/14656566.1.6.1195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
30 Malik P, Edginton A. Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies. Expert Opin Drug Metab Toxicol 2018;14:585-99. [PMID: 29806953 DOI: 10.1080/17425255.2018.1482278] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
31 Venkatesh MP, Weisman LE. Prevention and treatment of respiratory syncytial virus infection in infants: an update. Expert Review of Vaccines 2014;5:261-8. [DOI: 10.1586/14760584.5.2.261] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
32 Castilow EM, Olson MR, Meyerholz DK, Varga SM. Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. J Virol 2008;82:2196-207. [PMID: 18094193 DOI: 10.1128/JVI.01949-07] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
33 Feltes TF, Sondheimer HM. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease. Expert Opin Biol Ther 2007;7:1471-80. [PMID: 17727335 DOI: 10.1517/14712598.7.9.1471] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
34 Paes BA. Current strategies in the prevention of respiratory syncytial virus disease. Paediatr Respir Rev 2003;4:21-7. [PMID: 12615029 DOI: 10.1016/s1526-0542(02)00306-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
35 Reff ME, Heard C. A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Critical Reviews in Oncology/Hematology 2001;40:25-35. [DOI: 10.1016/s1040-8428(01)00132-9] [Cited by in Crossref: 43] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
36 Lopez OJ, Osorio FA. Role of neutralizing antibodies in PRRSV protective immunity. Vet Immunol Immunopathol 2004;102:155-63. [PMID: 15507302 DOI: 10.1016/j.vetimm.2004.09.005] [Cited by in Crossref: 215] [Cited by in F6Publishing: 210] [Article Influence: 11.9] [Reference Citation Analysis]
37 Morris SK, Dzolganovski B, Beyene J, Sung L. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect Dis 2009;9:106. [PMID: 19575815 DOI: 10.1186/1471-2334-9-106] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
38 Soto JA, Gálvez NMS, Pacheco GA, Bueno SM, Kalergis AM. Antibody development for preventing the human respiratory syncytial virus pathology. Mol Med 2020;26:35. [PMID: 32303184 DOI: 10.1186/s10020-020-00162-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
39 Resch B, Kurath-Koller S, Eibisberger M, Zenz W. Prematurity and the burden of influenza and respiratory syncytial virus disease. World J Pediatr 2016;12:8-18. [PMID: 26582294 DOI: 10.1007/s12519-015-0055-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
40 Ternant D, Paintaud G. Pharmacokinetics and concentration–effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opinion on Biological Therapy 2005;5:S37-47. [DOI: 10.1517/14712598.5.1.s37] [Cited by in Crossref: 89] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
41 Reuter SE, Evans AM, Ward MB. Reducing Palivizumab Dose Requirements Through Rational Dose Regimen Design. CPT Pharmacometrics Syst Pharmacol 2019;8:26-33. [PMID: 30426719 DOI: 10.1002/psp4.12364] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645-2668. [PMID: 15389672 DOI: 10.1002/jps.20178] [Cited by in Crossref: 645] [Cited by in F6Publishing: 566] [Article Influence: 37.9] [Reference Citation Analysis]
43 Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007;368:652-665. [PMID: 17362988 DOI: 10.1016/j.jmb.2007.02.024] [Cited by in Crossref: 245] [Cited by in F6Publishing: 228] [Article Influence: 16.3] [Reference Citation Analysis]
44 Makari D, Checchia PA, Devincenzo J. Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus. Hum Vaccin Immunother 2014;10:607-14. [PMID: 24316863 DOI: 10.4161/hv.27426] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
45 Robinson JL, Le Saux N; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Preventing hospitalizations for respiratory syncytial virus infection. Paediatr Child Health 2015;20:321-33. [PMID: 26435673 DOI: 10.1093/pch/20.6.321] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
46 Geskey JM, Ceneviva GD, Brummel GL, Graff GR, Javier MC. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit? Clin Ther 2004;26:2130-7. [PMID: 15823776 DOI: 10.1016/j.clinthera.2004.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
47 Garegnani L, Styrmisdóttir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JV. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev 2021;11:CD013757. [PMID: 34783356 DOI: 10.1002/14651858.CD013757.pub2] [Reference Citation Analysis]
48 Sáez-Llorens X, Moreno MT, Ramilo O, Sánchez PJ, Top FH Jr, Connor EM; MEDI-493 Study Group. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J 2004;23:707-12. [PMID: 15295219 DOI: 10.1097/01.inf.0000133165.85909.08] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 4.2] [Reference Citation Analysis]
49 Mitchell I, Paes B, Lanctot K, Chawla R, Chiu A, Mitchell M, Ojah C, Price A, Seigel S, Symington A. Letters to the Editor. Paediatr Child Health 2015;20:463-4. [PMID: 26744560 DOI: 10.1093/pch/20.8.463] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Joos B, Trkola A, Kuster H, Aceto L, Fischer M, Stiegler G, Armbruster C, Vcelar B, Katinger H, Günthard HF. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrob Agents Chemother 2006;50:1773-9. [PMID: 16641449 DOI: 10.1128/AAC.50.5.1773-1779.2006] [Cited by in Crossref: 51] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
51 Embleton ND, Dharmaraj ST, Deshpande S. Cost-effectiveness of palivizumab in infancy. Expert Rev Pharmacoecon Outcomes Res 2007;7:445-58. [PMID: 20528390 DOI: 10.1586/14737167.7.5.445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
52 Stowell CP. Therapy with immunoglobulin: applications for monoclonal antibodies. J Infus Nurs 2006;29:S29-44. [PMID: 16878853 DOI: 10.1097/00129804-200605001-00004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
53 Pescovitz MD, Knechtle S, Alexander SR, Colombani P, Nevins T, Nieforth K, Bouw MR. Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. Pediatr Transplant 2008;12:447-55. [PMID: 18466432 DOI: 10.1111/j.1399-3046.2007.00830.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
54 Kinder JT, Moncman CL, Barrett C, Jin H, Kallewaard N, Dutch RE. Respiratory Syncytial Virus and Human Metapneumovirus Infections in Three-Dimensional Human Airway Tissues Expose an Interesting Dichotomy in Viral Replication, Spread, and Inhibition by Neutralizing Antibodies. J Virol 2020;94:e01068-20. [PMID: 32759319 DOI: 10.1128/JVI.01068-20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
55 Null D Jr, Pollara B, Dennehy PH, Steichen J, Sánchez PJ, Givner LB, Carlin D, Landry B, Top FH Jr, Connor E. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr Infect Dis J 2005;24:1021-3. [PMID: 16282947 DOI: 10.1097/01.inf.0000183938.33484.bd] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
56 Meissner HC, Welliver RC, Chartrand SA, Law BJ, Weisman LE, Dorkin HL, Rodriguez WJ. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion: . The Pediatric Infectious Disease Journal 1999;18:223-31. [DOI: 10.1097/00006454-199903000-00004] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 3.1] [Reference Citation Analysis]
57 Resch B. Palivizumab for the prophylaxis of respiratory syncytial virus infection. Pediatric Health 2008;2:265-78. [DOI: 10.2217/17455111.2.3.265] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
58 Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol. 2010;184:1968-1976. [PMID: 20083659 DOI: 10.4049/jimmunol.0903296] [Cited by in Crossref: 242] [Cited by in F6Publishing: 218] [Article Influence: 20.2] [Reference Citation Analysis]
59 Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 2008;317:103-23. [PMID: 17990791 DOI: 10.1007/978-3-540-72146-8_4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 59] [Article Influence: 1.9] [Reference Citation Analysis]
60 Noor A, Fiorito T, Krilov LR. Cold Weather Viruses. Pediatr Rev 2019;40:497-507. [PMID: 31575801 DOI: 10.1542/pir.2018-0237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
61 Canfield SD, Simoes EAF. Prevention of Respiratory Syncytial Virus (RSV) Infection: RSV Immune Globulin Intravenous and Palivizumab. Pediatr Ann 1999;28:507-14. [DOI: 10.3928/0090-4481-19990801-08] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
62 Wu P, Escobar GJ, Gebretsadik T, Carroll KN, Li SX, Walsh EM, Mitchel EF, Sloan C, Dupont WD, Yu C, Horner JR, Hartert TV. Effectiveness of Respiratory Syncytial Virus Immunoprophylaxis in Reducing Bronchiolitis Hospitalizations Among High-Risk Infants. Am J Epidemiol 2018;187:1490-500. [PMID: 29351636 DOI: 10.1093/aje/kwy008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
63 [DOI: 10.1101/2020.06.05.135921] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Andrade CA, Pacheco GA, Gálvez NMS, Soto JA, Bueno SM, Kalergis AM. Innate Immune Components that Regulate the Pathogenesis and Resolution of hRSV and hMPV Infections. Viruses 2020;12:E637. [PMID: 32545470 DOI: 10.3390/v12060637] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
65 Resch B. Burden of respiratory syncytial virus infection in young children. World J Clin Pediatr 2012; 1(3): 8-12 [PMID: 25254161 DOI: 10.5409/wjcp.v1.i3.8] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
66 Ravasio R, Lucioni C, Chirico G. Costo-efficacia di palivizumab versus non profilassi nella prevenzione delle infezioni da VRS nei bambini pretermine, a diversa età gestazionale. Pharmacoeconomics-Ital-Res-Articles 2006;8:105-17. [DOI: 10.1007/bf03320561] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
67 Thwaites R, Edwards K, Buchan S. Reducing the burden of respiratory syncytial virus: An audit of the use of palivizumab prophylaxis in the UK during the September 2001–March 2002 RSV season. Journal of Neonatal Nursing 2008;14:116-23. [DOI: 10.1016/j.jnn.2007.12.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
68 Griffiths C, Drews SJ, Marchant DJ. Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment. Clin Microbiol Rev 2017;30:277-319. [PMID: 27903593 DOI: 10.1128/CMR.00010-16] [Cited by in Crossref: 190] [Cited by in F6Publishing: 118] [Article Influence: 38.0] [Reference Citation Analysis]
69 Co MS, Landolfi NF, Nagy JO, Tan JH, Vexler V, Vasquez M, Roark L, Yuan S, Hinton PR, Melrose J, Klingbeil C, Queen C, Berg EL. Properties and pharmacokinetics of two humanized antibodies specific for L-selectin. Immunotechnology 1999;4:253-66. [DOI: 10.1016/s1380-2933(98)00024-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
70 Groothuis JR, Hoopes JM, Hemming VG. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis. Adv Ther 2011;28:110-25. [PMID: 21318605 DOI: 10.1007/s12325-010-0101-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
71 Lewis AD, Chen R, Montefiori DC, Johnson PR, Clark KR. Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol 2002;76:8769-75. [PMID: 12163597 DOI: 10.1128/jvi.76.17.8769-8775.2002] [Cited by in Crossref: 84] [Cited by in F6Publishing: 55] [Article Influence: 4.2] [Reference Citation Analysis]
72 Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev 2013;:CD006602. [PMID: 23633336 DOI: 10.1002/14651858.CD006602.pub4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 51] [Article Influence: 3.0] [Reference Citation Analysis]
73 Jacobs SA, Wu S, Feng Y, Bethea D, O’neil KT. Cross-Interaction Chromatography: A Rapid Method to Identify Highly Soluble Monoclonal Antibody Candidates. Pharm Res 2010;27:65-71. [DOI: 10.1007/s11095-009-0007-z] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 5.2] [Reference Citation Analysis]
74 Figueras Aloy J, Quero J, Doménech E, López Herrera MC, Izquierdo I, Losada A, Perapch J, Sánchez-Luna M; Comité de Estándares de la Sociedad Española de Neonatología. [Recommendations for the prevention of respiratory syncytial virus infection]. An Pediatr (Barc) 2005;63:357-62. [PMID: 16219256 DOI: 10.1157/13079818] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
75 Weltzin R, Monath TP. Intranasal Antibody Prophylaxis for Protection against Viral Disease. Clin Microbiol Rev 1999;12:383-93. [DOI: 10.1128/cmr.12.3.383] [Cited by in Crossref: 52] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
76 Abraha HY, Lanctôt KL, Paes B. Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention. Expert Rev Respir Med 2015;9:779-99. [PMID: 26457970 DOI: 10.1586/17476348.2015.1098536] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
77 Zhang Y, Liu Y, Wang Y, Schultz PG, Wang F. Rational Design of Humanized Dual-Agonist Antibodies. J Am Chem Soc 2015;137:38-41. [DOI: 10.1021/ja510519u] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
78 Gojo J, Sauermann R, Knaack U, Slavc I, Peyrl A. Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies. Drugs R D 2017;17:469-74. [PMID: 28577293 DOI: 10.1007/s40268-017-0190-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
79 Fitzgerald DA, Isaacs D, Tobin B. Palivizumab: A debate about funding: Palivizumab. Journal of Paediatrics and Child Health 2012;48:373-7. [DOI: 10.1111/j.1440-1754.2010.01865.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
80 Paes BA, Craig C, Pigott W, Latchman A. Seasonal respiratory syncytial virus prophylaxis based on predetermined dates versus regional surveillance data. Pediatr Infect Dis J 2013;32:e360-4. [PMID: 23546534 DOI: 10.1097/INF.0b013e31829479d3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
81 Abarca K, Jung E, Fernández P, Zhao L, Harris B, Connor EM, Losonsky GA; Motavizumab Study Group. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. Pediatr Infect Dis J 2009;28:267-72. [PMID: 19258920 DOI: 10.1097/INF.0b013e31818ffd03] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
82 Soto JA, Stephens LM, Waldstein KA, Canedo-Marroquín G, Varga SM, Kalergis AM. Current Insights in the Development of Efficacious Vaccines Against RSV. Front Immunol 2020;11:1507. [PMID: 32765520 DOI: 10.3389/fimmu.2020.01507] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
83 Oral HB, Akdis CA. Antibody-based therapies in infectious diseases. Methods Mol Med 2000;40:157-78. [PMID: 21337089 DOI: 10.1385/1-59259-076-4:157] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
84 Langley JM, Aggarwal N, Toma A, Halperin SA, McNeil SA, Fissette L, Dewé W, Leyssen M, Toussaint JF, Dieussaert I. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant. J Infect Dis 2017;215:24-33. [PMID: 27694633 DOI: 10.1093/infdis/jiw453] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
85 Kuang B, King L, Wang HF. Therapeutic monoclonal antibody concentration monitoring: free or total? Bioanalysis 2010;2:1125-40. [DOI: 10.4155/bio.10.64] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 5.8] [Reference Citation Analysis]
86 Rajan A, Weaver AM, Aloisio GM, Jelinski J, Johnson HL, Venable SF, McBride T, Aideyan L, Piedra FA, Ye X, Melicoff-Portillo E, Yerramilli MRK, Zeng XL, Mancini MA, Stossi F, Maresso AW, Kotkar SA, Estes MK, Blutt S, Avadhanula V, Piedra PA. The human nose organoid respiratory virus model: an ex-vivo human challenge model to study RSV and SARS-CoV-2 pathogenesis and evaluate therapeutics. bioRxiv 2021:2021. [PMID: 34341793 DOI: 10.1101/2021.07.28.453844] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
87 Reilley S, Wenzel E, Reynolds L, Bennett B, Patti JM, Hetherington S. Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers. Antimicrob Agents Chemother 2005;49:959-62. [PMID: 15728889 DOI: 10.1128/AAC.49.3.959-962.2005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
88 Lacaze-Masmonteil T, Rozé JC, Fauroux B; French Pediatricians' Group of Sunagis Patients' Name-Based Programs. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis. Pediatr Pulmonol 2002;34:181-8. [PMID: 12203846 DOI: 10.1002/ppul.10175] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
89 Fuentes S, Arenas D, Moore MM, Golding H, Khurana S. Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines. Vaccine 2017;35:694-702. [PMID: 27989627 DOI: 10.1016/j.vaccine.2016.11.044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
90 Jones BG, Sealy RE, Rudraraju R, Traina-Dorge VL, Finneyfrock B, Cook A, Takimoto T, Portner A, Hurwitz JL. Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine 2012;30:959-68. [PMID: 22119594 DOI: 10.1016/j.vaccine.2011.11.046] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 5.0] [Reference Citation Analysis]
91 Groothuis JR, Nishida H. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab). Pediatr Int 2002;44:235-41. [PMID: 11982888 DOI: 10.1046/j.1442-200x.2002.01558.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
92 Wegzyn C, Toh LK, Notario G, Biguenet S, Unnebrink K, Park C, Makari D, Norton M. Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review. Infect Dis Ther 2014;3:133-58. [PMID: 25297809 DOI: 10.1007/s40121-014-0046-6] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
93 Bollani L, Baraldi E, Chirico G, Dotta A, Lanari M, Del Vecchio A, Manzoni P, Boldrini A, Paolillo P, Di Fabio S, Orfeo L, Stronati M, Romagnoli C; Italian Society of Neonatology. Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital J Pediatr 2015;41:97. [PMID: 26670908 DOI: 10.1186/s13052-015-0203-x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
94 Robbie GJ, Makari D, Harris B, Losonsky GA, Jafri HS. Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation. Infect Dis Ther 2014;3:203-14. [PMID: 25269648 DOI: 10.1007/s40121-014-0042-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
95 Paes B, Mitchell I, Li A, Harimoto T, Lanctôt KL. Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries. Clin Dev Immunol 2013;2013:917068. [PMID: 23861694 DOI: 10.1155/2013/917068] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
96 Montagna M, Visai L, Di Comite A, Iommiello V, Avanzini M, Bloise N, Stronati M, Regazzi M. Development and Validation of an Enzyme Linked Immunosorbent Assay for Palivizumab Serum Determination. Int J Immunopathol Pharmacol 2013;26:503-10. [DOI: 10.1177/039463201302600224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
97 Rennick LJ, Nambulli S, Lemon K, Olinger GY, Crossland NA, Millar EL, Duprex WP. Recombinant subtype A and B human respiratory syncytial virus clinical isolates co-infect the respiratory tract of cotton rats. J Gen Virol 2020;101:1056-68. [PMID: 32723429 DOI: 10.1099/jgv.0.001471] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
98 Paes B, Kim D, Saleem M, Wong S, Mitchell I, Lanctot KL; and the CARESS investigators. Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders. Eur J Pediatr 2019;178:377-85. [DOI: 10.1007/s00431-018-03308-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
99 Mills J. Prevention and Treatment of Respiratory Syncytial Virus Infections. In: Mills J, Volberding PA, Corey L, editors. Antiviral Chemotherapy 5. Boston: Springer US; 1999. pp. 39-53. [DOI: 10.1007/978-1-4615-4743-3_5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
100 Stobart CC, Moore ML. RNA virus reverse genetics and vaccine design. Viruses 2014;6:2531-50. [PMID: 24967693 DOI: 10.3390/v6072531] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 7.0] [Reference Citation Analysis]
101 Chen JJ, Chan P, Paes B, Mitchell I, Li A, Lanctôt KL; CARESS investigators. Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention. PLoS One 2015;10:e0134711. [PMID: 26237402 DOI: 10.1371/journal.pone.0134711] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
102 Bertoglio F, Meier D, Langreder N, Steinke S, Rand U, Simonelli L, Heine PA, Ballmann R, Schneider KT, Roth KDR, Ruschig M, Riese P, Eschke K, Kim Y, Schäckermann D, Pedotti M, Kuhn P, Zock-Emmenthal S, Wöhrle J, Kilb N, Herz T, Becker M, Grasshoff M, Wenzel EV, Russo G, Kröger A, Brunotte L, Ludwig S, Fühner V, Krämer SD, Dübel S, Varani L, Roth G, Čičin-Šain L, Schubert M, Hust M. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nat Commun 2021;12:1577. [PMID: 33707427 DOI: 10.1038/s41467-021-21609-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
103 Al-Alaiyan S, Pollack P, Notario GF. Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children. Drugs Context 2015;4:212270. [PMID: 25767550 DOI: 10.7573/dic.212270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
104 Claydon J, Popescu CR, Shaiba L, Christopherson C, Human D, Taylor R, Solimano A, Lavoie PM. Outcomes related to respiratory syncytial virus with an abbreviated palivizumab regimen in children with congenital heart disease: a descriptive analysis. CMAJ Open 2019;7:E88-93. [PMID: 30782771 DOI: 10.9778/cmajo.20180167] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
105 Gaboli M, de la Cruz ÒA, de Agüero MI, Moreno-Galdó A, Pérez GP, de Querol MS. Use of palivizumab in infants and young children with severe respiratory disease: a Delphi study. Pediatr Pulmonol 2014;49:490-502. [PMID: 23775884 DOI: 10.1002/ppul.22826] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
106 Fitzgerald DA. Preventing RSV bronchiolitis in vulnerable infants: The role of palivizumab. Paediatric Respiratory Reviews 2009;10:143-7. [DOI: 10.1016/j.prrv.2009.06.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
107 Scott LJ, Lamb HM. Palivizumab. Drugs 1999;58:305-11; discussion 312-3. [PMID: 10473022 DOI: 10.2165/00003495-199958020-00009] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
108 Meissner HC, Groothuis JR, Rodriguez WJ, Welliver RC, Hogg G, Gray PH, Loh R, Simoes EA, Sly P, Miller AK, Nichols AI, Jorkasky DK, Everitt DE, Thompson KA. Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease. Antimicrob Agents Chemother 1999;43:1183-8. [PMID: 10223933 DOI: 10.1128/AAC.43.5.1183] [Cited by in Crossref: 38] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
109 Cutrera R, Wolfler A, Picone S, Rossi GA, Gualberti G, Merolla R, Del Vecchio A, Villani A, Midulla F, Dotta A. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports. Ital J Pediatr 2019;45:139. [PMID: 31706338 DOI: 10.1186/s13052-019-0736-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
110 Ali ES, Rajapaksha H, Carr JM, Petrovsky N. Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens. Antiviral Res 2016;133:14-22. [PMID: 27421712 DOI: 10.1016/j.antiviral.2016.07.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
111 Simoes EA. Respiratory syncytial virus infection. Lancet 1999;354:847-52. [PMID: 10485741 DOI: 10.1016/S0140-6736(99)80040-3] [Cited by in Crossref: 274] [Cited by in F6Publishing: 141] [Article Influence: 11.9] [Reference Citation Analysis]
112 Edlund H, Melin J, Parra-Guillen ZP, Kloft C. Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children. Clin Pharmacokinet 2015;54:35-80. [PMID: 25516414 DOI: 10.1007/s40262-014-0208-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
113 Pignotti MS, Carmela Leo M, Pugi A, De Masi S, Biermann KP, Galli L, Vitali Rosati G, Buonocore G, Mugelli A, Dani C, Lucenteforte E, Bellini F, Donzelli G; Palivizumab Consensus Group. Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease. Pediatr Pulmonol 2016;51:1088-96. [PMID: 27618642 DOI: 10.1002/ppul.23561] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
114 Basu S, Lien YTK, Vozmediano V, Schlender JF, Eissing T, Schmidt S, Niederalt C. Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim. Front Pharmacol 2020;11:868. [PMID: 32595502 DOI: 10.3389/fphar.2020.00868] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
115 Peters TR, Crowe JE. Respiratory Syncytial Virus. Principles and Practice of Pediatric Infectious Disease. Elsevier; 2008. pp. 1112-6. [DOI: 10.1016/b978-0-7020-3468-8.50231-5] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
116 Rocca A, Biagi C, Scarpini S, Dondi A, Vandini S, Pierantoni L, Lanari M. Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now? Int J Mol Sci 2021;22:3703. [PMID: 33918185 DOI: 10.3390/ijms22073703] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
117 La Via WV, Notario GF, Yu XQ, Sharma S, Noertersheuser PA, Robbie GJ. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis. Pulm Pharmacol Ther 2013;26:666-71. [PMID: 23523663 DOI: 10.1016/j.pupt.2013.03.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
118 Embleton ND, Harkensee C, Mckean MC. Palivizumab for preterm infants. Is it worth it? Arch Dis Child Fetal Neonatal Ed 2005;90:F286-9. [PMID: 16036888 DOI: 10.1136/adc.2004.058081] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
119 Liu M, Yang G, Wiehe K, Nicely NI, Vandergrift NA, Rountree W, Bonsignori M, Alam SM, Gao J, Haynes BF, Kelsoe G. Polyreactivity and autoreactivity among HIV-1 antibodies. J Virol 2015;89:784-98. [PMID: 25355869 DOI: 10.1128/JVI.02378-14] [Cited by in Crossref: 120] [Cited by in F6Publishing: 98] [Article Influence: 15.0] [Reference Citation Analysis]
120 Resch B. Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants. Expert Rev Pharmacoecon Outcomes Res 2008;8:529-38. [PMID: 20528363 DOI: 10.1586/14737167.8.6.529] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
121 Resch B. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother 2017;13:2138-49. [PMID: 28605249 DOI: 10.1080/21645515.2017.1337614] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 11.6] [Reference Citation Analysis]
122 Elhalik M, El-Atawi K, Dash SK, Faquih A, Satyan AD, Gourshettiwar N, Khan A, Varughese S, Ramesh A, Khamis E. Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study. Can Respir J 2019;2019:2986286. [PMID: 31871513 DOI: 10.1155/2019/2986286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
123 Rijsbergen LC, Lamers MM, Comvalius AD, Koutstaal RW, Schipper D, Duprex WP, Haagmans BL, de Vries RD, de Swart RL. Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures. mSphere 2021;6:e00237-21. [PMID: 33980679 DOI: 10.1128/mSphere.00237-21] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Hashimoto K, Hosoya M. Neutralizing epitopes of RSV and palivizumab resistance in Japan. Fukushima J Med Sci 2017;63:127-34. [PMID: 28867684 DOI: 10.5387/fms.2017-09] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
125 González AE, Lay MK, Jara EL, Espinoza JA, Gómez RS, Soto J, Rivera CA, Abarca K, Bueno SM, Riedel CA, Kalergis AM. Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection. Virulence 2017;8:685-704. [PMID: 27911218 DOI: 10.1080/21505594.2016.1265725] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
126 Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, Moldt B, Khan A, Svabek C, McAuliffe JM, Wrapp D, Patel NK, Cook KE, Richter BWM, Ryan PC, Yuan AQ, Suzich JA. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med 2017;9:eaaj1928. [PMID: 28469033 DOI: 10.1126/scitranslmed.aaj1928] [Cited by in Crossref: 88] [Cited by in F6Publishing: 86] [Article Influence: 22.0] [Reference Citation Analysis]
127 Checchia PA, Nalysnyk L, Fernandes AW, Mahadevia PJ, Xu Y, Fahrbach K, Welliver RC Sr. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Pediatr Crit Care Med 2011;12:580-8. [PMID: 21200358 DOI: 10.1097/PCC.0b013e3182070990] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
128 Alharbi AS, Alqwaiee M, Al-Hindi MY, Mosalli R, Al-Shamrani A, Alharbi S, Yousef A, Al Aidaroos A, Alahmadi T, Alshammary A, Miqdad A, Said Y, Alnemri A. Bronchiolitis in children: The Saudi initiative of bronchiolitis diagnosis, management, and prevention (SIBRO). Ann Thorac Med 2018;13:127-43. [PMID: 30123331 DOI: 10.4103/atm.ATM_60_18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
129 Sung L, Alonzo TA, Gerbing RB, Aplenc R, Lange BJ, Woods WG, Feusner J, Franklin J, Patterson MJ, Gamis AS; Children's Oncology Group. Respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008;51:784-6. [PMID: 18680152 DOI: 10.1002/pbc.21710] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
130 Gill KL, Machavaram KK, Rose RH, Chetty M. Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics. Clin Pharmacokinet 2016;55:789-805. [PMID: 26818483 DOI: 10.1007/s40262-015-0361-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
131 Bertoglio F, Fühner V, Ruschig M, Heine PA, Abassi L, Klünemann T, Rand U, Meier D, Langreder N, Steinke S, Ballmann R, Schneider KT, Roth KDR, Kuhn P, Riese P, Schäckermann D, Korn J, Koch A, Chaudhry MZ, Eschke K, Kim Y, Zock-Emmenthal S, Becker M, Scholz M, Moreira GMSG, Wenzel EV, Russo G, Garritsen HSP, Casu S, Gerstner A, Roth G, Adler J, Trimpert J, Hermann A, Schirrmann T, Dübel S, Frenzel A, Van den Heuvel J, Čičin-Šain L, Schubert M, Hust M. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Cell Rep 2021;36:109433. [PMID: 34273271 DOI: 10.1016/j.celrep.2021.109433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]